LAUSR

About LAUSR
Donate
Contact Us

Follow us:

You are not signed in:

Sign Up!


   Articles with "mutated advanced" as a keyword



Population Pharmacokinetics and Exposure‐Response Analysis of First‐Line Osimertinib Plus Chemotherapy in Patients with EGFR‐Mutated Advanced NSCLC

Sign Up to like & get
recommendations! Published in 2025 at "Clinical Pharmacology and Therapeutics"

DOI: 10.1002/cpt.3759

Abstract: Osimertinib, a third‐generation, central nervous system‐active epidermal growth factor receptor‐tyrosine kinase inhibitor, potently and selectively inhibits epidermal growth factor receptor‐tyrosine kinase inhibitor sensitizing and T790M resistance mutations, with efficacy in epidermal growth factor receptor‐mutated non‐small… read more here.

Keywords: first line; factor receptor; mutated advanced; growth factor ... See more keywords

Gefitinib (an EGFR tyrosine kinase inhibitor) plus anlotinib (an multikinase inhibitor) for untreated, EGFR-mutated, advanced non-small cell lung cancer (FL-ALTER): a multicenter phase III trial

Sign Up to like & get
recommendations! Published in 2024 at "Signal Transduction and Targeted Therapy"

DOI: 10.1038/s41392-024-01927-9

Abstract: Dual inhibition of vascular endothelial growth factor and epidermal growth factor receptor (EGFR) signaling pathways offers the prospect of improving the effectiveness of EFGR-targeted therapy. In this phase 3 study (ClinicalTrial.gov: NCT04028778), 315 patients with… read more here.

Keywords: non small; plus anlotinib; advanced non; egfr mutated ... See more keywords

Phase 2 study of osimertinib in combination with platinum and pemetrexed in patients with previously untreated EGFR-mutated advanced non-squamous non-small cell lung cancer: The OPAL Study.

Sign Up to like & get
recommendations! Published in 2023 at "European journal of cancer"

DOI: 10.2139/ssrn.4329566

Abstract: BACKGROUND This multicenter phase 2 trial evaluated the safety and efficacy of osimertinib and platinum-based chemotherapy (OPP) in patients with previously untreated EGFR-mutated advanced non-squamous non-small cell lung cancer (NSCLC). PATIENTS AND METHODS Patients received… read more here.

Keywords: untreated egfr; previously untreated; mutated advanced; advanced non ... See more keywords